Applied Biosystems™ Axiom™ SARS-CoV-2 Research Array Genotyping Service
High-throughput, cost-effective genotyping and bioinformatics services for small to large-scale
Enabling Precision Medicine Research
The Ariel Precision Medicine array genotyping service provides high-throughput, cost-effective genotyping and associated bioinformatics services for small to large-scale research-initiatives. Ariel offers high-quality bioinformatic analyses using a secure and compliant cloud-based platform, to provide genotype calls, copy-number variant calls and quality metrics. Ariel is a preferred service provider for Thermo Fisher Scientific’s Applied Biosystems™ Axiom™ Human Genotyping SARS-CoV-2 Research Array. Ariel has completed their own technical validation to align with CLIA requirements.
Thermo Fisher Scientific’s Applied Biosystems™ Axiom™ SARS-CoV-2 Research Array enables precision medicine research. The array includes >6,000 actionable variants covering ACMG59 genes, >180,000 variants relevant to SARS-CoV-2 research, and over 725,000 genome-wide association study (GWAS) markers to support research initiatives working to identify risk associations of disease associations across multi-ethnic populations. The Biosystems™ Applied Biosystems™ Axiom™ SARS-CoV-2 Research Array was designed in collaboration with Ariel Precision Medicine and several other organizations and biobank research communities.